The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways - GBI Research Reports

The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways

The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways - GBI Research Reports
The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways
Published Dec 31, 2009
97 pages — Published Dec 31, 2009
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

SummaryGBI Research, the leading business intelligence provider, has released its latest research 'The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways'. The report provides insights on the biosimilars market revenues and growth until 2015. Further, the distribution of revenues across key geographies such as the US, the top five countries in Europe and Japan are provided in the report. The report discusses the latest developments in the regulatory landscape and the evolving biosimilars approval pathways in Europe, the US and Japan. In-depth analysis into the individual segments of biosimilars market, their market forecasts and potential are also provided. The study analyzes the competitive landscape including benchmarking of the leading companies in the biosimilars market. Finally, a key trends analysis of mergers and acquisitions and licensing agreements involving biosimilars, is also provided.This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.ScopeThe scope of this report includes:- Analysis on the regulations for biosimilars market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan- Market forecasts and potential for the biosimilars market from 2008 to 2015. The key biologics classes included are human growth hormones, granulocyte colony stimulating factors, insulins, interferons and erythropoietins- Market characterization data for biosimilars including market size, market share and market potential- Key drivers and restraints that have a significant impact on the market- Competitive landscape of global biosimilars market including benchmarking of the leading companies. The key companies discussed in this report are Teva, Sandoz, Hospira Inc, STADA Arzneimittel AG, Ratiopharm, Dr.Reddy's Laboratories and Biocon Ltd- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global biosimilars marketReasons to buyThe report will enable business development and marketing executives strategizing their product launches to- Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the US, Europe and Japan- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth - Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps - Develop key strategic initiatives by studying the key strategies of top competitors- Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety

  
Source:
Document ID
GBIHC016MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents 45
1.1 List of Tables61
1.2 List of Figures 72
2 Introduction91
2.1 GBI Research Report Guidance91
3 The Future of Biosimilars Market Overview107
Overview of the Biopharmaceutical Industry103
3.2 Comparison of Biosimilars with Generics131
3.3 Biopharmaceutical Manufacturing Process143
4 The Future of Biosimilars Market Characterization1716
4.1 Global Biosimilars Market Size and Forecasts171
The US Biosimilars Market Size and Forecasts181
4.3 Europe Biosimilars Market Size and Forecasts181
4.4 Japan Biosimilars Size and Market Forecasts191
4.5 Market Forecasts for Biosimilars201
4.5.1 Human Growth Hormone Biosimilars Markets202
4.5.2 Erythropoietin (EPO) Biosimilars Markets221
4.5.3 Granulocyte Colony Stimulating Factor (G-CSF) Biosimilars Markets232
4.6 Opportunity Analysis251
4.6.1 Interferon-alpha Biosimilars251
4.6.2 Interferon-beta Biosimilars262
Insulin and Insulin Analogs Biosimilars282
4.6.4 Monoclonal Antibodies301
4.7 Unmet Needs in the Biopharmaceutical Market303
5 The Future of Biosimilars Regulatory Landscape3332
5.1 Regulatory Landscape in the US331
5.1.1 Regulatory Framework for Biopharmaceutical Industry332
5.1.2 Evolution of Regulatory Pathways for Biosimilars352
5.1.3 Current Position on Biosimilars371
5.1.3.1 Comparison of the Eshoo Barton and the Waxman Legislative Proposals375
5.1.3.2 Approval of Omnitrope421
5.1.4 Drivers and Barriers421
5.2 Regulatory Landscape in Europe431
5.2.1 Regulatory Framework for Biopharmaceutical Industry431
5.2.2 Evolution of Regulatory Pathways for Biosimilars441
5.2.3 Current Position on Biosimilars451
5.2.3.1 Overarching Guidelines461
5.2.3.2 Quality Guidelines461
5.2.3.3 Non-Clinical and Clinical Guidelines471
5.2.3.4 Annexes Product Specific Guidelines471
5.2.3.5 Post-Authorization Requirements471
5.2.3.6 Data Exclusivity Period481
5.2.3.7 What Does this Mean to the Biosimilar Industry?491
5.2.4 The Bolar Type Provision491
5.2.5 The Comparability Exercise501
5.2.6 Biosimilars Approvals and Applications512
5.2.7 Issues Facing the European Biosimilars Industry531
5.2.7.1 Naming531
5.2.7.2 Labeling 531
5.2.7.3 Substitution / Interchangeability531
5.2.7.4 Pharmacovigilance541
5.2.8 Drivers for the European Biosimilars Market541
5.2.8.1 Patent Expiry of Key Biologic Drugs Will Boost the Market Potential541
5.2.8.2 Biosimilars Will be Widely accepted by Payers as a Means to Reduce Rising Healthcare Costs541
5.2.8.3 Leading Pharmaceutical Companies Eye Biosimilars as an Area of Growth 551
5.2.8.4 Biosimilar Manufacturers From Low Cost Emerging Countries Will Drive Market Expansion551
5.2.9 Barriers for the European Biosimilars Market551
5.2.9.1 Substitution Remains a Contentious Issue in Many European Countries 551
5.2.9.2 Barriers to Entry Remain High Due to a Complex and High Cost Manufacturing Process551
5.2.9.3 Tradeoff Between Patient Safety and Healthcare Costs Will Resist the Acceptance of Biosimilars551
5.2.10 Country Analysis - The United Kingdom551
5.2.10.1 Structure of the Healthcare System551
5.2.10.2 Pricing and Reimbursement Mechanisms561
5.2.10.3 Drivers and Barriers for Biosimilars561
5.2.11 Country Analysis - Germany561
5.2.11.1 Structure of the Healthcare System561
5.2.11.2 Pricing and Reimbursement Mechanisms571
5.2.11.3 Drivers and Barriers for Biosimilars571
5.2.12 Country Analysis - France581
5.2.12.1 Structure of the Healthcare System581
5.2.12.2 Pricing and Reimbursement Mechanisms581
5.2.12.3 Drivers and Barriers for Biosimilars591
5.2.13 Country Analysis - Spain591
5.2.13.1 Structure of the Healthcare System591
5.2.13.2 Pricing and Reimbursement Mechanisms591
5.2.13.3 Drivers and Barriers for Biosimilars601
5.2.14 Country Analysis - Italy611
5.2.14.1 Structure of the Healthcare System611
5.2.14.2 Pricing and Reimbursement Mechanisms611
5.2.14.3 Drivers and Barriers for Biosimilars611
5.3 The Regulatory Landscape in Japan621
5.3.1 The Regulatory Framework for the Biopharmaceutical Industry621
5.3.2 Evolution of Regulatory Pathways for Biosimilars631
5.3.3 Current Position on Biosimilars631
5.3.3.1 The First Biosimilar Approved641
5.3.4 Drivers and Barriers641
The Future of Biosimilars Competitive Landscape6527
6.1 The Costs of Biosimilar Development Are Higher Than That of Generics651
6.2 High Initial Investments Favors Growth of Biosimilars Players with Financial Strength661
6.3 Technical Expertise in Biopharmaceutical Development and Manufacturing Determines Strategic Positioning672
6.4 Leading Biosimilars Players691
6.4.1 Teva Pharmaceuticals Ltd691
6.4.1.1 Approved Biosimilars701
Dr. Reddy s Laboratories711
6.4.2.1 Approved Biosimilars711
6.4.3 Phage Biotechnology Corporation721
6.4.3.1 Pipeline731
6.4.4 Cangene Corporation732
6.4.5 Biopartners751
6.4.5.1 Approved Biosimilars751
Pipeline761
6.4.6 BioCon Ltd761
6.4.6.1 Approved Biosimilars771
6.4.7 BioGenerix AG781
6.4.7.1 Pipeline781
6.4.8 Apotex Inc791
Sandoz801
6.4.9.1 Approved Biosimilar Products811
6.4.10 Hospira Inc821
6.4.10.1 Approved Biosimilar Products821
6.4.11 Watson Pharmaceuticals831
STADA Arzneimittel AG841
6.4.13 ANALIZA, INC851
6.4.14 Reliance GeneMedix Plc861
6.4.14.1 Approved Biosimilar Products871
Momenta Pharmaceuticals881
6.4.15.1 Pipeline881
6.4.16 Microbix Biosystems Inc891
6.4.17 Dragon Pharmaceuticals902
The Future of Biosimilars Strategic Consolidations922
7.1 Mergers &Acquisitions921
7.1.1 Merck Acquires Insmed s Follow-On Biologics for $130m921
7.1.2 Teva and Lonza Joint Venture Targets Biosimilars921
7.1.3 GTC Enters a Follow-On-Biologic Founder Development Collaboration With Ag Research921
7.2 Licensing Deals921
7.2.1 Innogene Seals Deal With CIMAB To Market Biosimilars 921
7.2.2 Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon931
8 Appendix944
8.1 Market Definitions941
8.2 Abbreviations941
8.3 Research Methodology953
8.3.1 Coverage 961
8.3.2 Secondary Research961
8.3.3 Primary Research971
8.3.4 Expert Panel Validation971
8.4 Contact Us971
8.5 Disclaimer971

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways" Dec 31, 2009. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Biosimilars-Market-Forecasts-to-2015-Opportunity-Analysis-and-Regulatory-Pathways-2115-11>
  
APA:
GBI Research Reports. (2009). The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways Dec 31, 2009. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Biosimilars-Market-Forecasts-to-2015-Opportunity-Analysis-and-Regulatory-Pathways-2115-11>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.